EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Prognostic Factors in Newly Diagnosed High‐Grade Osteosarcoma—A Systematic Review

Elisa Tirtei iD, Sascha Wilk Michelsen iD, Lianne M Haveman iD, Cristina Meazza iD, Joana F Oliveira, Ayesha Rasool, Emanuela Palmerini iD, Will Wilson iD, Nathalie Gaspar iD, Sandra J Strauss iD, Andri Papakonstantinou iD, Fredrik Baecklund iD und 1 weitere

Cancer Medicine · 2025-07 · 14 (14)

DOI: 10.1002/cam4.71044 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cancer Medicine, online erschienen am 16.07.2025. Verfasst von Elisa Tirtei und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology, Regina Margherita Children's Hospital, Turin, Italy. Hauptthemen laut MEDLINE: Bone Neoplasms, Osteosarcoma. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pretreatment prognostic factors in newly diagnosed osteosarcoma are important for clinical management and stratifying patients in clinical trials. Such factors include the presence of metastases, primary tumor size, and site. Factors surrounded by controversy include pathological fracture, histologic subtype, and P‐glycoprotein expression. No prognostic tumor biomarker has been established. We performed a systematic review with the aim to compile available evidence for pretreatment prognostic factors and define optimal cut‐off values for patient stratification or further validation in the upcoming European FOSTER‐CabOS trial.

Methods

Predefined search terms were used to search PubMed, Web‐of‐science, and Embase for all studies investigating pretreatment prognostic factors in newly diagnosed osteosarcoma patients published 2000–2023. After applying strict inclusion and exclusion criteria, 49 papers were included.

Results

We found 14 factors investigated in at least two separate studies or in a single study using one discovery and at least one validation cohort.

Conclusions

We confirmed the prognostic value of patient age, presence of metastasis, tumor size, and site (axial vs. appendicular). Future studies of these factors should focus on specific patient populations and defining optimal cut‐off values. Although serum level of alkaline phosphatase and lactate dehydrogenase were associated with outcome, it remains unclear if they are independent of other prognostic factors. The prognostic value remains unclear for sex, pathological fracture, histologic subtype, and P‐glycoprotein expression. We could not establish any new prognostic biomarker. However, circulating tumor DNA in plasma and the G1/G2 RNA signature in diagnostic tumor biopsies show promise and will be further validated in the upcoming FOSTER‐CabOS trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone NeoplasmsOsteosarcomaHumansBiomarkers, TumorNeoplasm GradingPrognosis

Stichwörter der Autor:innen

newly diagnosedosteosarcomapretreatmentprognostic factorssystematic review

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pediatric Oncology, Regina Margherita Children's Hospital, Turin, Italy.
  • Department of Pediatric and Adolescence Medicine, Clinic for Pediatric Oncology and Hematology, University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Pediatric Department, Portuguese Institute of Oncology of Lisbon, Lisbon, Portugal.
  • UCL Cancer Institute, London, UK.

ORCID-Profile: Elisa Tirtei, Sascha Wilk Michelsen, Lianne M Haveman, Cristina Meazza, Emanuela Palmerini, Will Wilson, Nathalie Gaspar, Sandra J Strauss, Andri Papakonstantinou, Fredrik Baecklund

Zitieren

APA

Tirtei, E., Michelsen, S. W., Haveman, L. M., Meazza, C., Oliveira, J. F., Rasool, A., Palmerini, E., Wilson, W., Gaspar, N., Strauss, S. J., Papakonstantinou, A., Baecklund, F., & FOSTER Consortium (Fight OsteoSarcoma Through European Research), work package 4 on trials in newly diagnosed osteosarcoma (2025). Prognostic Factors in Newly Diagnosed High‐Grade Osteosarcoma—A Systematic Review. Cancer Medicine, 14(14). https://doi.org/10.1002/cam4.71044

Vancouver

Tirtei E, Michelsen SW, Haveman LM, Meazza C, Oliveira JF, Rasool A, et al. Prognostic Factors in Newly Diagnosed High‐Grade Osteosarcoma—A Systematic Review. Cancer Medicine. 2025;14(14). doi:10.1002/cam4.71044

BibTeX
@article{Tirtei2025,
  author = {Tirtei, Elisa and Michelsen, Sascha Wilk and Haveman, Lianne M and Meazza, Cristina and Oliveira, Joana F and Rasool, Ayesha and Palmerini, Emanuela and Wilson, Will and Gaspar, Nathalie and Strauss, Sandra J and Papakonstantinou, Andri and Baecklund, Fredrik and FOSTER Consortium (Fight OsteoSarcoma Through European Research), work package 4 on trials in newly diagnosed osteosarcoma, FOSTER Consortium (Fight OsteoSarcoma Through European Research), work package 4 on trials in newly diagnosed osteosarcoma},
  title = {Prognostic Factors in Newly Diagnosed High‐Grade Osteosarcoma—A Systematic Review},
  journal = {Cancer Medicine},
  year = {2025},
  volume = {14},
  number = {14},
  doi = {10.1002/cam4.71044}
}
Kostenlos starten →